Across TCGA pan-cancer cohorts, HAL Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HAL data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher HAL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HAL expression acts as an unfavorable survival marker.
LUSC are the cancer types where HAL Mutation most reproducibly stratifies survival.